BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 28507279)

  • 1. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
    Tian L; Zeng R; Wang X; Shen C; Lai Y; Wang M; Che G
    Oncotarget; 2017 Jul; 8(28):46425-46435. PubMed ID: 28507279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
    Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
    Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
    Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW
    Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.
    Gao R; Wang F; Wang Z; Wu Y; Xu L; Qin Y; Shi H; Tong Z
    Medicine (Baltimore); 2019 Apr; 98(14):e14979. PubMed ID: 30946324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
    Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
    Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
    Creaney J; Dick IM; Segal A; Musk AW; Robinson BW
    Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
    Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S
    Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
    Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
    Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
    Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
    Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
    Proto C; Signorelli D; Mallone S; Prelaj A; Lo Russo G; Imbimbo M; Galli G; Ferrara R; Ganzinelli M; Leuzzi G; Greco FG; Calareso G; Botta L; Gatta G; Garassino M; Trama A
    Clin Lung Cancer; 2019 Nov; 20(6):e652-e660. PubMed ID: 31377142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers and prognostic factors for malignant pleural mesothelioma.
    Vigneri P; Martorana F; Manzella L; Stella S
    Future Oncol; 2015; 11(24 Suppl):29-33. PubMed ID: 26638920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
    Creaney J; Francis RJ; Dick IM; Musk AW; Robinson BW; Byrne MJ; Nowak AK
    Clin Cancer Res; 2011 Mar; 17(5):1181-9. PubMed ID: 21177406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
    Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
    Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
    Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
    Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.
    Servais EL; Colovos C; Rodriguez L; Bograd AJ; Nitadori J; Sima C; Rusch VW; Sadelain M; Adusumilli PS
    Clin Cancer Res; 2012 May; 18(9):2478-89. PubMed ID: 22371455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
    Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E
    Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.
    Sato T; Suzuki Y; Mori T; Maeda M; Abe M; Hino O; Takahashi K
    Cancer Med; 2014 Oct; 3(5):1377-84. PubMed ID: 25045139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
    Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
    Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.